<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446199</url>
  </required_header>
  <id_info>
    <org_study_id>91493</org_study_id>
    <secondary_id>310184</secondary_id>
    <nct_id>NCT00446199</nct_id>
  </id_info>
  <brief_title>Low-dose Hormone Therapy for Relief of Vasomotor Symptoms</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Lowest Effective Dose of Combinations of Oral Drospirenone and 17 Beta-Estradiol for the Relief of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women Over a Treatment Period of 12 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the lowest effective dose of the study drug for the
      relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer
      HealthCare Pharmaceuticals, Inc.

      Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)</measure>
    <time_frame>Baseline until 12 weeks of treatment</time_frame>
    <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)</measure>
    <time_frame>Baseline until 4 weeks of treatment</time_frame>
    <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)</measure>
    <time_frame>Baseline until 12 weeks of treatment</time_frame>
    <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity of moderate to severe hot flushes minus baseline severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)</measure>
    <time_frame>Baseline until 4 weeks of treatment</time_frame>
    <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity of moderate to severe hot flushes minus baseline severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Vaginal pH</measure>
    <time_frame>Baseline until 12 weeks of treatment</time_frame>
    <description>Vaginal pH determined following speculum examination using vaginal pH paper and recorded on case report form (CRF). Absolute change calculated as week 12 pH minus baseline pH.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Vaginal Maturation Value</measure>
    <time_frame>Baseline until 12 weeks of treatment</time_frame>
    <description>Calculated as (percentage of superficial cells) + 0.5 * (percentage of intermediate cells). Absolute change calculated as week 12 value minus baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Subjects self-assessed symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Subjects self-assessed symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Subjects self-assessed symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Subjects self-assessed symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Subjects self-assessed symptom severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Subjects self-assessed presence or absence of symptom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Subjects self-assessed presence or absence of symptom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Subjects self-assessed presence or absence of symptom; and if present recorded average number of times per night: 1; 2 to 4; more than 4.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)</measure>
    <time_frame>Baseline until 12 weeks of treatment</time_frame>
    <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)</measure>
    <time_frame>Baseline until 4 weeks of treatment</time_frame>
    <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)</measure>
    <time_frame>Baseline until 12 weeks of treatment</time_frame>
    <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity moderate to severe hot flushes minus baseline severity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)</measure>
    <time_frame>Baseline until 4 weeks of treatment</time_frame>
    <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity moderate to severe hot flushes minus baseline severity.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">735</enrollment>
  <condition>Vasomotor Symptoms</condition>
  <condition>Hot Flashes</condition>
  <arm_group>
    <arm_group_label>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol (E2 0.3mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</intervention_name>
    <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
    <arm_group_label>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</intervention_name>
    <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
    <arm_group_label>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol (E2 0.3mg)</intervention_name>
    <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
    <arm_group_label>Estradiol (E2 0.3mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Postmenopausal women &gt;40 years of age experiencing a minimum of 7 to 8 moderate to severe
        hot flushes per day or 50 to 60 moderate to severe hot flushes per week

        Exclusion Criteria:

          -  The usual exclusion criteria for hormone therapy apply

          -  Intake of medications other than hormones affecting hot flushes
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Grange Park</city>
        <state>Illinois</state>
        <zip>60526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amite</city>
        <state>Louisiana</state>
        <zip>70422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paw Paw</city>
        <state>Michigan</state>
        <zip>49079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Sutter G, Schmelter T, Gude K, Schaefers M, Gerlinger C, Archer DF. Population pharmacokinetic/pharmacodynamic evaluation of low-dose drospirenone with 17β-estradiol in postmenopausal women with moderate to severe vasomotor symptoms. Menopause. 2014 Mar;21(3):236-42. doi: 10.1097/GME.0b013e31829c12e8.</citation>
    <PMID>23963309</PMID>
  </results_reference>
  <results_reference>
    <citation>Archer DF, Schmelter T, Schaefers M, Gerlinger C, Gude K. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause. 2014 Mar;21(3):227-35. doi: 10.1097/GME.0b013e31829c1431.</citation>
    <PMID>23963307</PMID>
  </results_reference>
  <results_reference>
    <citation>K. Gude; T. Schmelter; M. Schaefers; C. Gerlinger. Efficacy of low dose Angeliq (0.5 mg E2 and 0.25 or 0.5 mg DRSP) compared to Angeliq (1 mg E2 and 1, 2 or 3 mg DRSP) in postmenopausal women with moderate to severe hot flushes. Menopause, Vol. 19, No. 12, 2012 * 2012, P-36, p 1388</citation>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2007</study_first_submitted>
  <study_first_submitted_qc>March 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2007</study_first_posted>
  <results_first_submitted>March 23, 2012</results_first_submitted>
  <results_first_submitted_qc>March 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 18, 2012</results_first_posted>
  <disposition_first_submitted>December 10, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>December 10, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 14, 2009</disposition_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vasomotor symptom relief</keyword>
  <keyword>Postmenopausal women</keyword>
  <keyword>Severe to Moderate Vasomotor symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 79 centers in the United States from 26 Mar 2007 (date of first participant's first visit) to 03 Nov 2008 (date of last participant's last visit)</recruitment_details>
      <pre_assignment_details>2457 Screened; 1722 Screen Failures; 735 randomized; 726 treated (Safety Analysis Set, SAF); 710 Full Analysis Set (FAS, randomized subjects with Baseline vasomotor symptom (VMS) data, took ≥1 study dose plus ≥1 VMS data day postdose); 569 Per Protocol Set (PPS, all subjects in FAS with ≥75% study drug compliance and no major protocol violations).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
          <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
        <group group_id="P2">
          <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
          <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
        <group group_id="P3">
          <title>Estradiol (E2 0.3mg)</title>
          <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="184"/>
                <participants group_id="P3" count="185"/>
                <participants group_id="P4" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="181">SAF=all randomized participants who took at least 1 dose of study medication.</participants>
                <participants group_id="P2" count="183">SAF=all randomized participants who took at least 1 dose of study medication.</participants>
                <participants group_id="P3" count="182">SAF=all randomized participants who took at least 1 dose of study medication.</participants>
                <participants group_id="P4" count="180">SAF=all randomized participants who took at least 1 dose of study medication.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Baseline and Postdose VMS Data Available</title>
              <participants_list>
                <participants group_id="P1" count="178">FAS=all randomized participants with Baseline VMS data and at least 1 day VMS data postdose.</participants>
                <participants group_id="P2" count="177">FAS=all randomized participants with Baseline VMS data and at least 1 day VMS data postdose.</participants>
                <participants group_id="P3" count="179">FAS=all randomized participants with Baseline VMS data and at least 1 day VMS data postdose.</participants>
                <participants group_id="P4" count="176">FAS=all randomized participants with Baseline VMS data and at least 1 day VMS data postdose.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="160"/>
                <participants group_id="P2" count="164"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site termination</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization in Error</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliant with visit schedule</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hormone fear</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost interest in study participation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>In-/Exclusion criterion violated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Move</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
          <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
        <group group_id="B2">
          <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
          <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
        <group group_id="B3">
          <title>Estradiol (E2 0.3mg)</title>
          <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="178"/>
            <count group_id="B2" value="177"/>
            <count group_id="B3" value="179"/>
            <count group_id="B4" value="176"/>
            <count group_id="B5" value="710"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>The population included all randomized participants with Baseline VMS data and at least 1 day VMS data postdose. Full Analysis Set (FAS).</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="5.61"/>
                    <measurement group_id="B2" value="53.5" spread="5.77"/>
                    <measurement group_id="B3" value="53.3" spread="6.05"/>
                    <measurement group_id="B4" value="53.4" spread="6.46"/>
                    <measurement group_id="B5" value="53.5" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>The population included all randomized participants with Baseline VMS data and at least 1 day VMS data postdose. Full Analysis Set (FAS).</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="178"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="176"/>
                    <measurement group_id="B5" value="710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of participants with hysterectomy/oophorectomy</title>
          <description>The population included all randomized participants with Baseline VMS data and at least 1 day VMS data postdose. Full Analysis Set (FAS).</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>hysterectomized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="99"/>
                    <measurement group_id="B5" value="386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>oophorectomized</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>The population included all randomized participants with Baseline VMS data and at least 1 day VMS data postdose. Full Analysis Set (FAS).</description>
          <units>kg/sqm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.070" spread="6.0636"/>
                    <measurement group_id="B2" value="28.190" spread="5.6965"/>
                    <measurement group_id="B3" value="29.080" spread="5.7410"/>
                    <measurement group_id="B4" value="27.882" spread="5.7859"/>
                    <measurement group_id="B5" value="28.543" spread="5.8370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years since last menstruation at baseline</title>
          <description>The population included all randomized participants with Baseline VMS data and at least 1 day VMS data postdose. Full Analysis Set (FAS).</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.913" spread="8.6719"/>
                    <measurement group_id="B2" value="8.784" spread="7.9947"/>
                    <measurement group_id="B3" value="9.214" spread="8.1892"/>
                    <measurement group_id="B4" value="9.509" spread="8.9693"/>
                    <measurement group_id="B5" value="9.355" spread="8.4560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)</title>
        <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.</description>
        <time_frame>Baseline until 12 weeks of treatment</time_frame>
        <population>Full analysis set (Intention to Treat (ITT)) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)</title>
          <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.</description>
          <population>Full analysis set (Intention to Treat (ITT)) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
          <units>Hot Flushes per week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.515" lower_limit="-324.6" upper_limit="60.82"/>
                    <measurement group_id="O2" value="-54.125" lower_limit="-215.9" upper_limit="9.03"/>
                    <measurement group_id="O3" value="-44.389" lower_limit="-145.4" upper_limit="91.25"/>
                    <measurement group_id="O4" value="-30.020" lower_limit="-485.3" upper_limit="55.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in the number of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in the number of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in the number of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)</title>
        <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.</description>
        <time_frame>Baseline until 4 weeks of treatment</time_frame>
        <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)</title>
          <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.</description>
          <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
          <units>Hot Flushes per week</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.868" lower_limit="-276.63" upper_limit="60.82"/>
                    <measurement group_id="O2" value="-37.596" lower_limit="-162.15" upper_limit="35.00"/>
                    <measurement group_id="O3" value="-31.621" lower_limit="-141.44" upper_limit="37.91"/>
                    <measurement group_id="O4" value="-15.109" lower_limit="-666.33" upper_limit="27.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 4 in the number of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/ van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 4 in the number of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 4 in the number of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)</title>
        <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity of moderate to severe hot flushes minus baseline severity.</description>
        <time_frame>Baseline until 12 weeks of treatment</time_frame>
        <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)</title>
          <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity of moderate to severe hot flushes minus baseline severity.</description>
          <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9294" lower_limit="-3.000" upper_limit="0.480"/>
                    <measurement group_id="O2" value="-1.000" lower_limit="-3.000" upper_limit="0.443"/>
                    <measurement group_id="O3" value="-0.2638" lower_limit="-3.000" upper_limit="0.337"/>
                    <measurement group_id="O4" value="-0.0698" lower_limit="-3.000" upper_limit="0.542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in the mean daily severity of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in the mean daily severity of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in the mean daily severity of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0096</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)</title>
        <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity of moderate to severe hot flushes minus baseline severity.</description>
        <time_frame>Baseline until 4 weeks of treatment</time_frame>
        <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Median Value)</title>
          <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity of moderate to severe hot flushes minus baseline severity.</description>
          <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
          <units>Scorese on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2905" lower_limit="-3.000" upper_limit="0.383"/>
                    <measurement group_id="O2" value="-0.1821" lower_limit="-2.800" upper_limit="1.267"/>
                    <measurement group_id="O3" value="-0.0651" lower_limit="-2.898" upper_limit="0.380"/>
                    <measurement group_id="O4" value="0.0000" lower_limit="-3.000" upper_limit="0.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 4 in the mean daily severity of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 4 in the mean daily severity of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 4 in the mean daily severity of hot flushes is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <p_value_desc>Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Vaginal pH</title>
        <description>Vaginal pH determined following speculum examination using vaginal pH paper and recorded on case report form (CRF). Absolute change calculated as week 12 pH minus baseline pH.</description>
        <time_frame>Baseline until 12 weeks of treatment</time_frame>
        <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Vaginal pH</title>
          <description>Vaginal pH determined following speculum examination using vaginal pH paper and recorded on case report form (CRF). Absolute change calculated as week 12 pH minus baseline pH.</description>
          <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
          <units>(pH)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="169"/>
                <count group_id="O3" value="169"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.874"/>
                    <measurement group_id="O2" value="-0.63" spread="0.935"/>
                    <measurement group_id="O3" value="-0.66" spread="0.967"/>
                    <measurement group_id="O4" value="-0.06" spread="0.698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in vaginal pH is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in vaginal pH is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3 mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in vaginal pH is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Vaginal Maturation Value</title>
        <description>Calculated as (percentage of superficial cells) + 0.5 * (percentage of intermediate cells). Absolute change calculated as week 12 value minus baseline value.</description>
        <time_frame>Baseline until 12 weeks of treatment</time_frame>
        <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Vaginal Maturation Value</title>
          <description>Calculated as (percentage of superficial cells) + 0.5 * (percentage of intermediate cells). Absolute change calculated as week 12 value minus baseline value.</description>
          <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
          <units>Percentages of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.07" spread="28.638"/>
                    <measurement group_id="O2" value="11.71" spread="29.185"/>
                    <measurement group_id="O3" value="7.69" spread="25.627"/>
                    <measurement group_id="O4" value="-2.41" spread="20.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in vaginal maturation value is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in vaginal maturation value is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The distribution of the change from baseline to week 12 in vaginal maturation value is identical in both arms, alternative: there is a shift in the distribution.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon/van Elteren</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'</title>
        <description>Subjects self-assessed symptom severity</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Dryness'</title>
          <description>Subjects self-assessed symptom severity</description>
          <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0314</p_value>
            <p_value_desc>no correction for multiplicity</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8780</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5908</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'</title>
        <description>Subjects self-assessed symptom severity</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal and/or Vulvar Irritation/Itching'</title>
          <description>Subjects self-assessed symptom severity</description>
          <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="146"/>
                    <measurement group_id="O4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>no correction for multiplicity</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4463</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0303</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'</title>
        <description>Subjects self-assessed symptom severity</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Dysuria'</title>
          <description>Subjects self-assessed symptom severity</description>
          <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="170"/>
                <count group_id="O4" value="162"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="169"/>
                    <measurement group_id="O3" value="167"/>
                    <measurement group_id="O4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4397</p_value>
            <p_value_desc>no correction for multiplicity</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0132</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3250</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'</title>
        <description>Subjects self-assessed symptom severity</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Pain Associated With Sexual Activity'</title>
          <description>Subjects self-assessed symptom severity</description>
          <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="127"/>
                    <measurement group_id="O4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9555</p_value>
            <p_value_desc>no correction for multiplicity</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1743</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4395</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'</title>
        <description>Subjects self-assessed symptom severity</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Symptoms of Vulvar and Vaginal Atrophy: Severity of Symptom 'Vaginal Bleeding Associated With Sexual Activity'</title>
          <description>Subjects self-assessed symptom severity</description>
          <population>Full analysis set. Numbers differ from the complete full analysis set due to missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
                <count group_id="O2" value="165"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>none</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="162"/>
                    <measurement group_id="O3" value="159"/>
                    <measurement group_id="O4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8966</p_value>
            <p_value_desc>no correction for multiplicity</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7512</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo on complete 2*4 table</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8751</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification by center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'</title>
        <description>Subjects self-assessed presence or absence of symptom</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Urogenital Symptoms: Number of Participants With Symptom 'Frequent Urination'</title>
          <description>Subjects self-assessed presence or absence of symptom</description>
          <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1067</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification for center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6011</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification for center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4408</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'</title>
        <description>Subjects self-assessed presence or absence of symptom</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Urogenital Symptoms: Number of Participants With Symptom 'Involuntary Urination When Laughing or Coughing'</title>
          <description>Subjects self-assessed presence or absence of symptom</description>
          <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="172"/>
                <count group_id="O2" value="170"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0144</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification for center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5589</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification for center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5500</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'</title>
        <description>Subjects self-assessed presence or absence of symptom; and if present recorded average number of times per night: 1; 2 to 4; more than 4.</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Urogenital Symptoms: Number of Participants With Symptom 'Urination at Night'</title>
          <description>Subjects self-assessed presence or absence of symptom; and if present recorded average number of times per night: 1; 2 to 4; more than 4.</description>
          <population>Full analysis set (ITT). Numbers differ from the complete full analysis set due to missing data.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="171"/>
                <count group_id="O3" value="172"/>
                <count group_id="O4" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2179</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification for center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7749</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification for center</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison of active treatment arm with placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8307</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Stratification for center</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)</title>
        <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.</description>
        <time_frame>Baseline until 12 weeks of treatment</time_frame>
        <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)</title>
          <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 12 number of moderate to severe hot flushes minus baseline number.</description>
          <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
          <units>Hot Flushes per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.331" spread="37.5217"/>
                    <measurement group_id="O2" value="-55.317" spread="30.2311"/>
                    <measurement group_id="O3" value="-41.783" spread="32.6122"/>
                    <measurement group_id="O4" value="-31.916" spread="44.4507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 12 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment, center and baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-27.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-33.2</ci_lower_limit>
            <ci_upper_limit>-22.0</ci_upper_limit>
            <estimate_desc>Change in active treatment arm minus change in placebo arm</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 12 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment, center and baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-22.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-27.8</ci_lower_limit>
            <ci_upper_limit>-16.6</ci_upper_limit>
            <estimate_desc>Change in active treatment arm minus change in placebo arm</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 12 is identical in both arms, alternative: there is a difference in the mean change from baseline</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment, center and baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-15.4</ci_lower_limit>
            <ci_upper_limit>-4.2</ci_upper_limit>
            <estimate_desc>Change in active treatment arm minus change in placebo arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)</title>
        <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.</description>
        <time_frame>Baseline until 4 weeks of treatment</time_frame>
        <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Weekly Frequency of Moderate to Severe Hot Flushes (Mean Value)</title>
          <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Absolute change calculated as week 4 number of moderate to severe hot flushes minus baseline number.</description>
          <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
          <units>Hot Flushes per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.810" spread="35.7876"/>
                    <measurement group_id="O2" value="-38.989" spread="27.7812"/>
                    <measurement group_id="O3" value="-32.633" spread="28.1349"/>
                    <measurement group_id="O4" value="-24.195" spread="54.7480"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 4 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment, center and baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-23.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-29.9</ci_lower_limit>
            <ci_upper_limit>17.8</ci_upper_limit>
            <estimate_desc>Change in active treatment arm minus change in placebo arm</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 4 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment, center and baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-20.2</ci_lower_limit>
            <ci_upper_limit>-8.1</ci_upper_limit>
            <estimate_desc>Change in active treatment arm minus change in placebo arm</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 4 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0054</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment, center and baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-14.6</ci_lower_limit>
            <ci_upper_limit>-2.5</ci_upper_limit>
            <estimate_desc>Change in active treatment arm minus change in placebo arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)</title>
        <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity moderate to severe hot flushes minus baseline severity.</description>
        <time_frame>Baseline until 12 weeks of treatment</time_frame>
        <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)</title>
          <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 12 severity moderate to severe hot flushes minus baseline severity.</description>
          <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="178"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4473" spread="1.11616"/>
                    <measurement group_id="O2" value="-1.2141" spread="1.08299"/>
                    <measurement group_id="O3" value="-0.7822" spread="1.03497"/>
                    <measurement group_id="O4" value="-0.3873" spread="0.76950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 12 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment, center and baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.069</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.280</ci_lower_limit>
            <ci_upper_limit>-0.859</ci_upper_limit>
            <estimate_desc>Change in active treatment arm minus change in placebo arm</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 12 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment, center and baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.803</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.013</ci_lower_limit>
            <ci_upper_limit>-0.593</ci_upper_limit>
            <estimate_desc>Change in active treatment arm minus change in placebo arm</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 12 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>treatment, center and baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.361</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.570</ci_lower_limit>
            <ci_upper_limit>-0.152</ci_upper_limit>
            <estimate_desc>Change in active treatment arm minus change in placebo arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)</title>
        <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity moderate to severe hot flushes minus baseline severity.</description>
        <time_frame>Baseline until 4 weeks of treatment</time_frame>
        <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O2">
            <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
            <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O3">
            <title>Estradiol (E2 0.3mg)</title>
            <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Weekly Mean Daily Severity of Moderate to Severe Hot Flushes (Mean Value)</title>
          <description>Subjects record daily on the diary cards the frequency and severity of hot flushes during the treatment period as none, mild, moderate or severe. Daily score is calculated as [(2 x number of moderate hot flushes) + (3 x number of severe hot flushes)] / (total number of moderate to severe hot flushes on that day). Range = 0 (lowest severity) to 3 (highest severity). Absolute change calculated as week 4 severity moderate to severe hot flushes minus baseline severity.</description>
          <population>Full analysis set (ITT) with last observation carried forward approach (LOCF). Numbers differ from the complete full analysis set due to missing Week 1 data.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="174"/>
                <count group_id="O3" value="177"/>
                <count group_id="O4" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8347" spread="1.02226"/>
                    <measurement group_id="O2" value="-0.5859" spread="0.89106"/>
                    <measurement group_id="O3" value="-0.4033" spread="0.73774"/>
                    <measurement group_id="O4" value="-0.1926" spread="0.63585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.5mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 4 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment, Center, and Baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.635</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.813</ci_lower_limit>
            <ci_upper_limit>-0.458</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between DRSP/E2 (0.25mg/0.5mg) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 4 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment, Center, and Baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.382</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.560</ci_lower_limit>
            <ci_upper_limit>-0.205</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison between E2 (0.3) and Placebo with respect to a shift in the distribution of the end point. Null hypothesis: The mean change from baseline to week 4 is identical in both arms, alternative: there is a difference in the mean change from baseline.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0233</p_value>
            <p_value_desc>Significance level of 1.7% is used to adjust (Bonferroni) for the comparison of three active arms with Placebo.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Treatment, Center, and Baseline value used as covariate</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.204</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.381</ci_lower_limit>
            <ci_upper_limit>-0.028</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>0.5mg DRSP / 0.5mg E2 (BAY86-4891)</title>
          <description>One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
        <group group_id="E2">
          <title>0.25mg DRSP / 0.5mg E2 (BAY86-4891)</title>
          <description>One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
        <group group_id="E3">
          <title>Estradiol (E2 0.3mg)</title>
          <description>One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle)</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Oropharyngeal cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="75" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="68" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="181"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>(A) PI will provide copy to Sponsor at least (30) days prior to date of planned submission or presentation. Sponsor will have thirty (30) days to review and provide feedback. If proposed publication presents material adverse effect on the confidentiality of Sponsor's information, then PI shall delay or prevent such publication. (B) In a multi-center trial, the investigative data will be pooled and published as a collaborative effort with consent from all parties including the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

